Nycomed US Plans Growth Through Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
Now that Takeda has entered into a $13 billion deal to buy Nycomed, the U.S. affiliate, which isn't part of the deal, plans to grow sales by 10% annually through 2015.
You may also be interested in...
As Takeda Integrates Its Nycomed Acquisition, Europe Bears Brunt Of Job Cuts
Takeda is to close two R&D facilities in Germany and to cut commercial activities in the U.S., as it looks for cost savings from the 2011 acquisition of Nycomed.
Nycomed US Crowns New Management; Plans New Direction
Now that Japan's Takeda Pharmaceuticals Co. Ltd. is just months away from closing on its €9.6 billion ($13.7 billion) purchase of privately-held Nycomed AS, the Swiss company's investors are planning plenty of changes for the U.S. dermatology business that wasn’t included in the large acquisition.
Nycomed US Crowns New Management; Plans New Direction
Now that Japan's Takeda Pharmaceuticals Co. Ltd. is just months away from closing on its €9.6 billion ($13.7 billion) purchase of privately-held Nycomed AS, the Swiss company's investors are planning plenty of changes for the U.S. dermatology business that wasn’t included in the large acquisition.